FA14s3.i
Merge
PascalFrancis
Racine
Merge
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Merge (PascalFrancis)

Index « FA14s3.i » - entrée « CZE »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
CHN < CZE < DEU  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 5.
Ident.Authors (with country if any)Title
000004 (2006) R. N. Maini ; P. C. Taylor ; J. Szechinski ; K. Pavelka ; J. Bröll ; G. Balint ; P. Emery ; F. Raemen ; J. Petersen ; J. Smolen ; D. Thomson ; T. KishimotoDouble-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate
000060 (2010) J. L. Nam ; K. L. Winthrop ; R. F. Van Vollenhoven ; K. Pavelka ; G. Valesini ; E. M. A. Hensor ; G. Worthy ; R. Landewe ; J. S. Smolen ; P. Emery ; M. H. BuchCurrent evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
000172 (2012) Karel Pavelka ; Arthur F. Kavanaugh ; Andrea Rubbert-Roth ; Gianfranco FerraccioliOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
000189 (2012) Vivian P. Bykerk ; Andrew J. K. Östör ; José Alvaro-Gracia ; Karel Pavelka ; José Andrés Román Ivorra ; Winfried Graninger ; William Bensen ; Michael T. Nurmohamed ; Andreas Krause ; Corrado Bernasconi ; Andrea Stancati ; Jean SibiliaTocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
000211 (2013) Cem Gabay ; Paul Emery ; Ronald Van Vollenhoven ; Ara Dikranian ; Rieke Alten ; Karel Pavelka ; Micki Klearman ; David Musselman ; Sunil Agarwal ; Jennifer Green ; Arthur KavanaughTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PascalFrancis/Merge

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Merge/FA14s3.i -k "CZE" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Merge/FA14s3.i  \
                -Sk "CZE" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Merge/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PascalFrancis
   |étape=   Merge
   |type=    indexItem
   |index=    FA14s3.i
   |clé=    CZE
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021